Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synercid, Zyvox Drug Pricing Discourages Use, IDSA Rep Says

Executive Summary

The cost of Aventis' Synercid and Pharmacia's Zyvox discourages use of the drugs for resistant disease pathogens, Infectious Disease Society of America representative Louis Rice, MD, Louis Stokes Cleveland Veterans Affairs Medical Center, told FDA's Anti-Infective Drugs Advisory Committee

You may also be interested in...



FDA Flexible With Accelerated Approval Evidence, Analysis Finds

Attorneys Sasinowski and Varond write that in some cases weak clinical evidence on the surrogate endpoint was not a barrier, but strong findings on unmet need and rarity usually are necessary for accelerated approval.

Antibiotic Research Stalling In Conversion Of Target Into New Drug

Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7

Antibiotic Research Stalling In Conversion Of Target Into New Drug

Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7

Related Content

UsernamePublicRestriction

Register

PS039459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel